Compare INO & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INO | CPIX |
|---|---|---|
| Founded | 1979 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 92.3M |
| IPO Year | 1999 | 2007 |
| Metric | INO | CPIX |
|---|---|---|
| Price | $1.10 | $7.85 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.75 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 64.0K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.18 | ★ 58.70 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $42,220,086.00 | $42,010,949.00 |
| Revenue This Year | $20,156.19 | N/A |
| Revenue Next Year | $421.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.37 | 16.75 |
| 52 Week Low | $1.03 | $1.85 |
| 52 Week High | $2.86 | $8.09 |
| Indicator | INO | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 40.11 | 65.39 |
| Support Level | $1.03 | $5.53 |
| Resistance Level | $1.24 | N/A |
| Average True Range (ATR) | 0.06 | 0.73 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 14.29 | 96.14 |
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.